GlucoMetrix AG successfully completes the development of a manufacturing process for recombinant human insulin. With this new manufacturing process insulin can be produced at lower cost in comparison with traditional methods. Starting signal for the production for the clinical phase is 2010. Article to download (in english) GlucoMetrix plc is set to grow despite the global financial crisis. Bavarian Biotech enterprise doubles the number of the co-workers and plans further expansion and fast growth. Article to download (in german) GlucoMetrix plc has moved to Potsdam, Brandenburg for biotechnologically engineered insulin development The Bavarian LifeScience enterprise GlucoMetrix plc settles its development in Potsdam, Brandenburg. The enterprise plans on a long-term basis to create 250 new jobs. Article to download (in german) Early recognition of the diabetic risk: in the future based on fingerprint and palmary dermatoglyphics. The GlucoMetrix plc develops a new computer-assisted algorithm for the early risk recognition of Diabetes mellitus. Article to download (in german) Bavarian company develops new insulin GlucoMetrix plc from Ruhpolding, Bavaria, is with the new biotechnologically engineered insulin already shortly before the clinical phase testing. The world-wide insulin demand is growing rapidly. Article to download (in german)